MMPs in Cardiovascular Diseases: Emerging Pharmacological Targets

2013 ◽  
pp. 407-426 ◽  
Author(s):  
Aastha Chhabra ◽  
Shrey Kohli ◽  
Vibha Rani
Keyword(s):  
Cardiovascular Diseases ◽  
Pharmacological Targets

The biological activity of high-density lipoprotein fractions and their role in the development of cardiovascular diseases

2016 ◽  
Vol 88 (9) ◽  
pp. 111-118 ◽  
Author(s):  
Ya D Babintseva ◽  
L Camont ◽  
J Chapman ◽  
M Lhomme ◽  
V P Karagodin ◽  
...  
Keyword(s):  
Biological Activity ◽  
Cardiovascular Diseases ◽  
Density Lipoprotein ◽  
Compositional Analysis ◽  
Biological Properties ◽  
High Density ◽  
High Density Lipoproteins ◽  
Pharmacological Targets ◽  
New Findings ◽  
Protein Rich

Increasing the human plasma concentration of high-density lipoproteins (HDL) may be part of strategy for control of cardiovascular diseases (CVD). HDL particles vary in their structure, metabolism, and biological activity. The review describes major HDL fractions (subpopulations) and discusses new findings on the antiatherogenic properties of HDL particles. The whole spectrum of HDL fractions, small, dense, protein-rich lipoproteins, has atheroprotective properties that are determined by the presence of specialized groups of proteins and lipids; however, this activity may be decreased in atherogenic lesion. Comprehensive structural and compositional analysis of HDL may provide key information to identify the fractions that have characteristic biological properties and lose their functionality in CVD. These fractions may be also biomarkers for the risk of CVD and hence represent pharmacological targets.

Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer

2005 ◽  
Vol 11 (16) ◽  
pp. 2119-2134 ◽  
Author(s):  
E. Paulhe ◽  
S. Manenti ◽  
L. Ysebaert ◽  
R. Betous ◽  
P. Sultan ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Pharmacological Targets

scholarly journals Search for new pharmacological targets for increasing the efficiency of correction of cardiovascular diseases

2019 ◽  
Vol 5 (3) ◽  
pp. 67-77
Author(s):  
Liliya V. Korokina ◽  
Ivan V. Golubev ◽  
Olga N. Pokopejko ◽  
Anastasia V. Zagrebelnaya ◽  
Sergey A. Demchenko
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Cardiovascular Diseases ◽  
High Risk ◽  
Endothelial Dysfunction ◽  
New Targets ◽  
Pharmacological Targets ◽  
The World ◽  
Pharmacological Correction

Introduction: Cardiovascular disease (CVD) is the leading cause of death worldwide: no other reason causes as many deaths a year as CVD. An estimated 17.9 million people died of CVD in 2016, accounting for 31% of all deaths in the world. People with CVD or at high risk for these diseases (due to one or more risk factors, such as high blood pressure, diabetes, hyperlipidemia, or an already developed disease) need early detection and assistance through counseling and, if necessary, taking medication. Ways to find new targets for the correction of endothelium-associated pathology: The basis of the modern therapy for arterial hypertension and other cardiovascular diseases is the postulate of the need to correct endothelial dysfunction as an indication of the adequacy of antihypertensive and other types of treatment. Lowering blood pressure (BP) without normalizing endothelial function cannot be considered a successfully resolved clinical task. Currently, there are no drugs for specific pharmacological correction of endothelial dysfunction in cardiovascular diseases, and the search for new targets for pharmacological correction of endothelial dysfunction is one of the main tasks of pharmacology.

Inflammageing in the cardiovascular system: mechanisms, emerging targets, and novel therapeutic strategies

2020 ◽  
Vol 134 (17) ◽  
pp. 2243-2262
Author(s):  
Danlin Liu ◽  
Gavin Richardson ◽  
Fehmi M. Benli ◽  
Catherine Park ◽  
João V. de Souza ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Cardiovascular System ◽  
Nlrp3 Inflammasome ◽  
Molecular Mechanisms ◽  
Molecular Targets ◽  
Therapeutic Interventions ◽  
Low Grade ◽  
Cardiovascular Research ◽  
Inflammatory Processes ◽  
Ach Receptors

Abstract In the elderly population, pathological inflammation has been associated with ageing-associated diseases. The term ‘inflammageing’, which was used for the first time by Franceschi and co-workers in 2000, is associated with the chronic, low-grade, subclinical inflammatory processes coupled to biological ageing. The source of these inflammatory processes is debated. The senescence-associated secretory phenotype (SASP) has been proposed as the main origin of inflammageing. The SASP is characterised by the release of inflammatory cytokines, elevated activation of the NLRP3 inflammasome, altered regulation of acetylcholine (ACh) nicotinic receptors, and abnormal NAD+ metabolism. Therefore, SASP may be ‘druggable’ by small molecule therapeutics targeting those emerging molecular targets. It has been shown that inflammageing is a hallmark of various cardiovascular diseases, including atherosclerosis, hypertension, and adverse cardiac remodelling. Therefore, the pathomechanism involving SASP activation via the NLRP3 inflammasome; modulation of NLRP3 via α7 nicotinic ACh receptors; and modulation by senolytics targeting other proteins have gained a lot of interest within cardiovascular research and drug development communities. In this review, which offers a unique view from both clinical and preclinical target-based drug discovery perspectives, we have focused on cardiovascular inflammageing and its molecular mechanisms. We have outlined the mechanistic links between inflammageing, SASP, interleukin (IL)-1β, NLRP3 inflammasome, nicotinic ACh receptors, and molecular targets of senolytic drugs in the context of cardiovascular diseases. We have addressed the ‘druggability’ of NLRP3 and nicotinic α7 receptors by small molecules, as these proteins represent novel and exciting targets for therapeutic interventions targeting inflammageing in the cardiovascular system and beyond.

Self-efficacy and quality of life among people with cardiovascular diseases: A meta-analysis.

2018 ◽  
Vol 63 (2) ◽  
pp. 295-312 ◽  
Author(s):  
Anna Banik ◽  
Ralf Schwarzer ◽  
Nina Knoll ◽  
Katarzyna Czekierda ◽  
Aleksandra Luszczynska
Keyword(s):  
Quality Of Life ◽  
Cardiovascular Diseases ◽  
Self Efficacy ◽  
Meta Analysis

Mitochondria as pharmacological targets for anxiolytic treatment

2015 ◽  
Vol 48 (06) ◽  
Author(s):  
M Nussbaumer ◽  
J Asara ◽  
L Teplytska ◽  
M Murphy ◽  
R Landgraf ◽  
...  
Keyword(s):  
Pharmacological Targets

Apolipoprotein(a), Fibrinopeptide A and Carotid Atherosclerosis in Middle-Aged Men

1994 ◽  
Vol 72 (04) ◽  
pp. 563-566 ◽  
Author(s):  
Tuomo Rankinen ◽  
Sari Väisänen ◽  
Michele Mercuri ◽  
Rainer Rauramaa
Keyword(s):  
Risk Factors ◽  
Cardiovascular Diseases ◽  
Carotid Atherosclerosis ◽  
Intima Media Thickness ◽  
Carotid Bifurcation ◽  
Carotid Intima Media Thickness ◽  
Fibrinopeptide A ◽  
Carotid Imt ◽  
Apolipoprotein A ◽  
The Difference

SummaryThe association between apolipoprotein(a) [apo(a)], fibrinogen, fibrinopeptide A (FPA) and carotid intima-media thickness (IMT) was analyzed in Eastern Finnish men aged 50 to 60 years. Apo(a) correlated directly with carotid bifurcation (r = 0.26, p = 0.001), but not with common carotid IMT. Men in the lowest quartile of apo(a) had thinner (p = 0.013) IMT in bifurcation [1.59 mm (95% Cl 1.49; 1.68)] compared to the men in the highest [1.91 mm (95% Cl 1.73; 2.09)] apo(a) quartile. The difference remained (p=0.038) after adjusting for confounders. Plasma fibrinogen was not related to carotid IMT, whereas FPA correlated with common carotid (r = 0.21, p = 0.016) and carotid bifurcation (r = 0.21, p = 0.018) IMT. These associations abolished after adjusting for the confounders. The data suggest that apo(a) associate with carotid atherosclerosis independent of other risk factors for ischemic cardiovascular diseases.

Sign in / Sign up

Export Citation Format

Share Document